OncoSil Medical

Sydney, Australia Founded: 2005 • Age: 21 yrs
A brachytherapy device for pancreatic cancer treatment is developed.
Request Access

About OncoSil Medical

OncoSil Medical is a company based in Sydney (Australia) founded in 2005.. OncoSil Medical offers products and services including OncoSil™. OncoSil Medical operates in a competitive market with competitors including Sana Biotechnology, Janux Therapeutics, Carisma Therapeutics, GigaGen and Kronos Bio, among others.

  • Headquarter Sydney, Australia
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Oncosil Medical Ltd
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $764.01 K (USD)
    126.62
    as on Jun 30, 2025
  • Net Profit
    $-9.86 M (USD)
    -26.74
    as on Jun 30, 2025
  • EBITDA
    $-10.07 M (USD)
    -18.7
    as on Jun 30, 2025
  • Latest Funding Round
    $8.7 M (USD), Post-IPO

    May 26, 2025

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of OncoSil Medical

OncoSil Medical is a publicly listed company on the ASX with ticker symbol OSL in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: ASX · Ticker: OSL . Sector: Health technology · Australia

Products & Services of OncoSil Medical

OncoSil Medical offers a comprehensive portfolio of products and services, including OncoSil™. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Delivers targeted radiation to pancreatic tumors with chemotherapy.

People of OncoSil Medical
Headcount 10-50
Employee Profiles 11
Employee Profiles
People
Henk Tissing
Director, Global Head Of Clinical Affairs
People
Christian Dal Cin
Chief Financial Officer
People
Jon Bell
Chief Medical Officer
People
Antonio Ponce Cuesta
Regional Head Spain & Portugal

Unlock access to complete

Funding Insights of OncoSil Medical

  • Total Funding
  • Total Rounds 4
  • Last Round Post-IPO — $8.7M
  • First Round

    (01 Jun 2005)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
May, 2025 Amount Post-IPO - OncoSil Medical Valuation

investors

Apr, 2022 Amount Post-IPO - OncoSil Medical Valuation

investors

Feb, 2016 Amount Post-IPO - OncoSil Medical Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in OncoSil Medical

OncoSil Medical has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Regal Funds Management. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Long/short investment strategy is followed by this hedge fund.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by OncoSil Medical

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - OncoSil Medical

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Oncosil Medical Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of OncoSil Medical

OncoSil Medical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Janux Therapeutics, Carisma Therapeutics, GigaGen and Kronos Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Genetically engineered cell therapies are developed for multiple disorders.
domain founded_year HQ Location
Immunotherapeutics for cancer treatment are developed to target solid tumors.
domain founded_year HQ Location
Chimeric antigen receptor macrophages are developed for cancer treatment.
domain founded_year HQ Location
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
domain founded_year HQ Location
Small molecule therapeutics for cancer treatment are developed.
domain founded_year HQ Location
Antibody-based drugs for primary myopathies are developed and targeted.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Oncosil Medical

Frequently Asked Questions about OncoSil Medical

When was OncoSil Medical founded?

OncoSil Medical was founded in 2005.

Where is OncoSil Medical located?

OncoSil Medical is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.

What is the annual revenue of OncoSil Medical?

Annual revenue of OncoSil Medical is $764.01K as on Jun 30, 2025.

What does OncoSil Medical do?

OncoSil Medical was founded in 2005 in Sydney, Australia, within the medical device sector focused on oncology. Operations center on the development of OncoSil, a brachytherapy implant that delivers beta radiation via phosphorous-32 microparticles to target cancer cell DNA in the pancreas. Proprietary diluents are used as carriers for precise implantation into affected tissues, supporting localized treatment approaches.

Who are the top competitors of OncoSil Medical?

OncoSil Medical's top competitors include Janux Therapeutics, Kronos Bio and Sana Biotechnology.

What products or services does OncoSil Medical offer?

OncoSil Medical offers OncoSil™.

Is OncoSil Medical publicly traded?

Yes, OncoSil Medical is publicly traded on ASX under the ticker symbol OSL.

Who are OncoSil Medical's investors?

OncoSil Medical has 1 investor. Key investors include Regal Funds Management.

What is OncoSil Medical's ticker symbol?

The ticker symbol of OncoSil Medical is OSL on ASX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available